Loading...
•
Dec 31, 2021
Bruker Q4 2021 Earnings Report
Bruker's Q4 2021 financial results were reported, showing revenue growth and EPS increase.
Key Takeaways
Bruker reported Q4 2021 revenues of $683.5 million, an 8.9% increase year-over-year, with organic revenue growth of 11.4%. GAAP EPS was $0.50, and non-GAAP EPS was $0.59, up $0.01 year-over-year. The company anticipates solid organic revenue and non-GAAP EPS growth in FY 2022.
Q4 2021 revenues reached $683.5M, reflecting an 8.9% year-over-year increase.
Organic revenue growth for Q4 2021 was 11.4% year-over-year.
Q4 2021 GAAP EPS stood at $0.50, while non-GAAP EPS reached $0.59, a $0.01 increase year-over-year.
Bruker anticipates robust organic revenue and non-GAAP EPS growth in FY 2022, driven by investments in Project Accelerate 2.0 initiatives.
Bruker
Bruker
Bruker Revenue by Segment
Bruker Revenue by Geographic Location
Revenue by Segment
BEST Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Bruker expects approximately 5% to 7% year-over-year revenue growth, including organic revenue growth of approximately 6% to 8%, M&A contribution of approximately 1%, and foreign currency translation headwind of approximately -2%. In FY 2022, Bruker expects non-GAAP operating margin expansion of 30 bps to 60 bps year-over-year, from 19.4% in FY 2021. Finally, Bruker expects FY 2022 non-GAAP EPS of $2.29 to $2.33, a 9% to 11% increase year-over-year.
Positive Outlook
- Approximately 5% to 7% year-over-year revenue growth is expected.
- Organic revenue growth of approximately 6% to 8% is anticipated.
- M&A is expected to contribute approximately 1%.
- Non-GAAP operating margin expansion of 30 bps to 60 bps year-over-year is projected.
- FY 2022 non-GAAP EPS is expected to be $2.29 to $2.33, a 9% to 11% increase year-over-year.
Challenges Ahead
- Foreign currency translation headwind of approximately -2% is expected.
- Supply chain and inflation challenges will likely persist through H1 2022.
- First-half operating margins are expected to be about 500-600 bps lower than second-half operating margins.
- R&D investments are planned to be approximately 10% of revenue during FY 2022.
- Unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort.